JP2018507876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507876A5 JP2018507876A5 JP2017546738A JP2017546738A JP2018507876A5 JP 2018507876 A5 JP2018507876 A5 JP 2018507876A5 JP 2017546738 A JP2017546738 A JP 2017546738A JP 2017546738 A JP2017546738 A JP 2017546738A JP 2018507876 A5 JP2018507876 A5 JP 2018507876A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- day
- group
- disease
- neurodegenerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000004503 fine granule Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002569 neurons Anatomy 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- -1 poultice Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Claims (5)
- 神経変性疾患の処置および予防に使用するための化合物であって、該化合物は、
- 前記神経変性疾患がパーキンソン病である、請求項１に記載の化合物。
- 前記化合物が、錠剤、微粒剤、カプセル剤、カシェ剤、トローチ、ロゼンジ、分散剤、坐剤、軟膏剤、パップ剤、ペースト剤、粉末剤、ドレッシング材、クリーム剤、硬膏剤、溶液、貼付剤、エアロゾル剤、ゲル剤、エリキシル剤、シロップ剤、懸濁液、ウェーハ、および注射剤から成る群から選択される剤形で存在する、請求項１に記載の化合物。
- 前記化合物が、α−シヌクレインの神経細胞内の蓄積を減少させることに活性である、請求項１に記載の化合物。
- 前記化合物が、約０．１ｍｇ／ｋｇ／日から約２００ｍｇ／ｋｇ／日までの用量で投与される、請求項１に記載の化合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562177187P | 2015-03-09 | 2015-03-09 | |
| US62/177,187 | 2015-03-09 | ||
| PCT/US2016/016294 WO2016144441A1 (en) | 2015-03-09 | 2016-02-03 | Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507876A JP2018507876A (ja) | 2018-03-22 |
| JP2018507876A5 true JP2018507876A5 (ja) | 2019-03-14 |
| JP6684524B2 JP6684524B2 (ja) | 2020-04-22 |
Family
ID=56879251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546738A Active JP6684524B2 (ja) | 2015-03-09 | 2016-02-03 | 神経変性疾患の処置または予防のためのハイポエストキシド、その誘導体、関連化合物、およびアゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10857122B2 (ja) |
| EP (1) | EP3267992A4 (ja) |
| JP (1) | JP6684524B2 (ja) |
| CN (1) | CN107530312A (ja) |
| AU (1) | AU2016229520B2 (ja) |
| CA (1) | CA2978869C (ja) |
| HK (1) | HK1249044A1 (ja) |
| WO (1) | WO2016144441A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3267992A4 (en) | 2015-03-09 | 2018-12-05 | Immune Modulation, Inc. | Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases |
| ES2932081T3 (es) * | 2019-04-15 | 2023-01-11 | Nanologica Ab | Partículas porosas vacías para su uso en el tratamiento, la prevención y/o el retraso de la degeneración de enfermedades neurodegenerativas, neuronas y glía |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001871A (en) * | 1998-01-15 | 1999-12-14 | Immune Modulation, Inc. | Hypoestoxides, derivatives and agonists thereof for use as antiviral agents |
| US5801193A (en) * | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
| EP1043991A4 (en) * | 1997-11-14 | 2005-02-02 | Lilly Co Eli | TREATMENT OF ALZHEIMER DISEASE |
| BR0306632A (pt) * | 2002-10-28 | 2004-09-28 | Paraquest Inc | Hipoestóxidos, seus derivados e agonistas para uso no tratamento e profilaxia de hiperlipidemia |
| US7674599B2 (en) * | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| US8124654B2 (en) * | 2008-11-11 | 2012-02-28 | Immune Modulation, Inc. | Derivatives of hypoestoxide and related compounds |
| WO2010065927A2 (en) | 2008-12-05 | 2010-06-10 | California Institute Of Technology | Dna-damage-induced proteolysis |
| EP3267992A4 (en) | 2015-03-09 | 2018-12-05 | Immune Modulation, Inc. | Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases |
-
2016
- 2016-02-03 EP EP16762089.7A patent/EP3267992A4/en active Pending
- 2016-02-03 CA CA2978869A patent/CA2978869C/en active Active
- 2016-02-03 CN CN201680026926.5A patent/CN107530312A/zh active Pending
- 2016-02-03 JP JP2017546738A patent/JP6684524B2/ja active Active
- 2016-02-03 AU AU2016229520A patent/AU2016229520B2/en active Active
- 2016-02-03 WO PCT/US2016/016294 patent/WO2016144441A1/en active Application Filing
- 2016-02-03 US US15/556,730 patent/US10857122B2/en active Active
-
2018
- 2018-07-09 HK HK18108865.5A patent/HK1249044A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017057230A5 (ja) | ||
| JP2015155440A5 (ja) | ||
| JP2011068653A5 (ja) | ||
| JP2012255026A5 (ja) | ||
| JP2019503365A5 (ja) | ||
| JP2011105760A5 (ja) | ||
| JP2016536286A5 (ja) | ||
| JP2009535352A5 (ja) | ||
| EA201001592A1 (ru) | Гомеопатическое лекарственное средство | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2017506624A5 (ja) | ||
| JP2014526503A5 (ja) | ||
| JP2013155188A5 (ja) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2014511393A5 (ja) | ||
| JP2015515985A5 (ja) | ||
| JP2019530706A5 (ja) | ||
| JP2019218379A5 (ja) | ||
| JP2018530578A5 (ja) | ||
| JP2018507876A5 (ja) | ||
| JP2016505050A5 (ja) | ||
| JP2018524306A5 (ja) | ||
| RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| JP2016528171A5 (ja) | ||
| EA201101622A1 (ru) | Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования |